Methods of promoting long-term survival of patients with advanced chemotherapy-resistant malignancies
OwnerErlinda M. Gordon, Frederick L. Hallinventors
Life of this patent
Estimating the term…
Abstract
Disclosed are methods for treating an individual with a chemotherapy-resistant primary and/or secondary malignancy that comprise administering a therapeutically effective amount of a tumor-targeted retrovector encoding a cytocidal dominant-negative Cyclin G1 construct, such as DeltaRex-G, to the individual. Also disclosed are methods in which DeltaRex-G, either alone or in conjunction with other cancer therapies and/or treatments, may be administered to ameliorate or eliminate the life-threatening effects of metastatic cancer.
Claims23
A method of treating an individual having a chemotherapy-resistant malignancy comprising,
- a. administering a therapeutically effective amount of a tumor-targeted retrovector to the individual, wherein the retrovector encodes a cytocidal dominant-negative cyclin G1 construct.
10-21. (canceled)
A method for improving the long-term survival of an individual with a metastatic tumor, the method comprising:
- a. identifying whether the metastatic tumor exhibits at least one of CCNG1 overexpression, Myc amplification, or genetic mutations along the CCNG1 axis including IGH-CCNG1 gene rearrangement;
- and,
- b. administering a high-dose, therapeutically effective amount of a CCNG1 inhibitor to the individual if the metastatic tumor exhibits at least one of CCNG1 overexpression and Myc amplification, or adding an alternative therapy if the tumor does not exhibit at least one of CCNG1 overexpression and Myc amplification or genetic mutations along the CCNG1 axis.
29-32. (canceled)
A method for preventing occurrence of a secondary malignancy in an individual having a tumor load, the method comprising:
- a. administering a CCNG1 inhibitor to the individual in a therapeutically effective total dose over a treatment period of up to 15 weeks;
- and
- b. administering no further anti-cancer therapy to the individual after the treatment period.
37-66. (canceled)
Dependencies are inferred from the claim text.